secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0001564590-22-027769
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotech Q2 revenue $43.7M (+13% YoY); MRD up 38%, net loss widens
--------------------------------------------------------------------------

- Revenue $43.7M (+13% YoY); MRD revenue $21.3M (+38%) on 53% test volume growth; Immune Medicine $22.4M (-3%).
- Net loss $52.1M vs $49.3M in Q2 2021; operating expenses $96.2M (+9% YoY).
- Updated FY2022 opex guidance to $410-415M (from $425-435M); revenue reaffirmed at $185-195M.
- Expanded Medicare coverage of clonoSEQ for MRD assessment in DLBCL; signed pan-portfolio agreement with major partner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000156459022027769/0001564590-22-027769-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000156459022027769/adpt-8k_20220803.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-027769

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer